Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc (OVID)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ovid Therapeutics Inc 441 Ninth Avenue 14th Floor New York NY 10001 USA

www.ovidrx.com Employees: 40 P: 646-661-7661 F: 646-661-4027

Description:

Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States.

Key Statistics

Overview:

Market Capitalization, $K 81,587
Enterprise Value, $K 54,547
Shares Outstanding, K 70,945
Annual Sales, $ 390 K
Annual Net Income, $ -52,340 K
Last Quarter Sales, $ 170 K
Last Quarter Net Income, $ 8,520 K
EBIT, $ -68,160 K
EBITDA, $ -66,560 K
60-Month Beta 0.39
% of Insider Shareholders 13.30%
% of Institutional Shareholders 72.24%
Float, K 61,509
% Float 86.70%
Short Volume Ratio 0.22

Growth:

1-Year Return -68.14%
3-Year Return -68.06%
5-Year Return -0.43%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 64.93%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.12 on 08/13/24
Next Earnings Date 11/01/24
Earnings Per Share ttm -0.43
EPS Growth vs. Prev Qtr 170.59%
EPS Growth vs. Prev Year 166.67%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 12/02/20

OVID Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -33.40%
Return-on-Assets % -22.94%
Profit Margin % -13,420.51%
Debt/Equity 0.00
Price/Sales 208.21
Price/Cash Flow N/A
Price/Book 0.87
Book Value/Share 1.25
Interest Coverage -0.68
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar